Lipoprotein (a) in patients with proteinuria

Miles, Thomas J.; Freestone, Alyssa; Varghese, Zac; Persaud, J.W.; Moorhead, John F.

doi:10.1093/ndt/7.7.597

Cited by 53 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevations in Lp(a) serum levels have been documented in adults with proteinuria (24)(25)(26), adults with end-stage renal failure treated by hemodialysis (27), renal allograft recipients (28), and children (33) and adults (34) with diabetes mellitus. In addition, alcohol intake (35) and possibly treatment with corticosteroids (25) may have an effect on serum Lp(a) levels.…”

Section: Discussionmentioning

confidence: 99%

“…Lp(a) can be detected in umbilical cord blood and serum of newborns (20)(21)(22), and a gradual rise in serum levels has been observed between the ages of 2 and 13 y (23). Previous studies in adults reported increased Lp(a) levels in patients with proteinChronic renal disease is often accompanied by severe dyslipi- (24)(25)(26) and in patients treated with hemdialysis (27) and demia, a known risk factor for cardiovascular disease. In adults, renal transplantation (28).…”

Section: ~H~ Distribution Of Lp(a) Levels In Normal Subjects Wasmentioning

confidence: 99%

See 1 more Smart Citation

Lipoprotein(a) Serum Levels and Apolipoprotein(a) Phenotypes in Children with Chronic Renal Disease

et al. 1993

View full text Add to dashboard Cite

ABSTRACT. Lipoprotein(a) [Lp(a)] has recently beenLp(a) is a cholesterol-rich lipoprotein resembling LDL, but characterized as a genetically determined risk factor for with a different protein composition, consisting of apo B-100 atherosclerosis and thrombosis. Normally, Lp(a) serum and apo(a). Increased blood concentrations of Lda) are strongly levels are closely related to the apo(a) phenotype. We associated with an increased risk for atherosclerosis (8-10) and studied Lp(a) serum levels and apo(a) phenotypes in 136 arterial and venous thrombosis (1 1). Notably in Young patients, young subjects, aged 0.8-24.7 y, including patients with Lda) appears to be an independent risk factor for myocardial glomerular disease and normal renal function (n = 28), infarction ( 12). The proatherogenic and prothrombotic effects of patients with chronic renal failure (n = 201, patients treated Lp Of all, 21 patients had proteinuria in the nephrotic range. and interference with the fibrinol~tic system (8, 99 13). ~h~ distribution of Lp(a) levels in normal subjects wasIn adult Caucasian populations, Lp(a) blood levels are usually skewed to the left with 97% having levels below 300 mg/ low, i.e. the distribution of normal values is shifted to the left; blood levels above 250-300 mg/L indicate a significant risk for L' A subpopulation with increased Lp(a) levels (13-42%) vascular complications, particularly in patients with elevated could be detected in all groups with renal disease, and LDL cholesterol levels (13-15). increased mean serum L P (~) levels were found in patients In individuals, L~~) serum levels are under genetic with ne~hrotic range proteinuria, in patients with chronic control and dependent on the phenotype of the apoprotein renal failure, and in patients on peritoneal dialysis. Serum apo(a). According to Utemann el (16), seven phenotypes of Lda) levels were not with age, gender, type Of different molecular weight can be differentiated by their relative renal disease, renal function or severity of proteinuria, but mobilities to apo B-100 on electrophoresis; these have been were ~ornelat* with the apo(a) phenotype. For a given designated F (faster than B-100), B (similar to B-loo), S 1, S2, phen?w9 Lda) levels knded t 0 . h higher in patients S3, S4 (all slower than B-loo), and 0 (not detectable). Serum than controls. We ~onclude that increased Lda) serum levels of Lp(a) show an inverse correlation with the size of the levels are frequently found in Young patients with chronic apoprotein phenotype, i.e. small phenotypes (F, B, Sl) are assorenal disease, possibly predisposing them to an increased ciated with high and larger phenotypes (S3, S4) with low serum risk for atherosclerosis and thrombosis. (Pediatr Res 34: levels of Lp(a) (16). Although Lp(a) levels for a given phenotype 772-776,1993) show considerable overlap, it was concluded that about 40% of the variability in the Lp(a) serum concentrations can be exAbbreviations plained by the apo(a) phenotype (17). Other researchers have identified a greater number of ...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: ~H~ Distribution Of Lp(a) Levels In Normal Subjects Wasmentioning

confidence: 99%

Lipoprotein(a) Serum Levels and Apolipoprotein(a) Phenotypes in Children with Chronic Renal Disease

et al. 1993

View full text Add to dashboard Cite

show abstract

“…Significantly higher cholesterol levels are present in the more buoyant LDL fractions (fractions 12-18) of the intensively treated group. A trend can be seen toward lower cholesterol content in the intermediate-density lipoprotein (IDL) fractions (fractions [19][20][21][22][23][24][25][26][27][28][29][30] in the intensively treated group, although this did not reach statistical significance.…”

Section: Dgucmentioning

confidence: 99%

“…Lp(a) levels have been shown to be higher in familial hypercholesterolemia [13], chronic renal failure [14][15][16][17][18][19], and nephrotic syndrome [20][21][22][23][24][25], and lower levels have been reported in cirrhosis [26]. How Lp(a) levels might be affected by IDDM and its complications and whether Lp(a) contributes to CAD [27,28] in this population remain controversial.…”

Section: Introductionmentioning

confidence: 99%

Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial

Purnell¹,

Marcovina²,

Hokanson³

et al. 1995

Diabetes

View full text Add to dashboard Cite

Levels of lipoprotein (a) [Lp(a)], apolipoprotein (apo) B, and lipoprotein cholesterol distribution using density-gradient ultracentrifugation were measured as part of a cross-sectional study at the final follow-up examination (mean 6.2 years) in the Diabetes Control and Complications Trial. Compared with the subjects in the conventionally treated group (n = 680), those subjects receiving intensive diabetes therapy (n = 667) had a lower level of Lp(a) (Caucasian subjects only, median 10.7 vs. 12.5 mg/dl, respectively; P = 0.03), lower apo B (mean 83 vs. 86 mg/dl, respectively; P = 0.01), and a more favorable distribution of cholesterol in the lipoprotein fractions as measured by density-gradient ultracentrifugation with less cholesterol in the very-low-density lipoprotein and the dense low-density lipoprotein fractions and greater cholesterol content of the more buoyant lowdensity lipoprotein. Compared with a nondiabetic Caucasian control group (n = 2,158), Lp(a) levels were not different in the intensive treatment group (median 9.6 vs. 10.7 mg/dl, respectively; NS) and higher in the conventional treatment group (9.6 vs. 12.5 mg/dl, respectively; P less than 0.01). No effect of renal dysfunction as measured by increasing albuminuria or reduced creatinine clearance on Lp(a) levels could be demonstrated in the diabetic subjects. Prospective follow-up of these subjects will determine whether these favorable lipoprotein differences in the intensive treatment group persist and whether they influence the onset of atherosclerosis in insulin-dependent diabetes. Lp(a) is formed by a molecule of a carbohydrate-rich protein named apo(a) linked by a single disulfide bond to the apo B of an LDL-like lipoprotein. Like LDL, Lp(a) is thought to be atherogeic. Because of the structural homology of apo(a) to plasminogen, it is also thought to have thrombogenic properties. This potential combination of proatherogenic and prothrombotic properties has led to a surge of research into the role of Lp(a) in atherosclerosis. KeywordsIn several case-controlled and prospective studies consisting primarily of white men with at least one preexisting cardiac risk factor, such as a family history of heart disease or an elevated LDL cholesterol level, an increased Lp(a) level has been shown to be an independent risk factor for CAD [5,10,11].Because up to 91 percent of the variability in plasma Lp(a) levels between individuals has been attributed to the apo(a) isoform [5,12], the contribution of age, sex, diet, and exercise to Lp(a) levels is thought to be small. Lp(a) levels have been shown to be higher in familial hypercholesterolemia [13], chronic renal failure [14][15][16][17][18][19], and nephrotic syndrome [20][21][22][23][24][25], and lower levels have been reported in cirrhosis [26]. How Lp(a) levels might be affected by IDDM and its complications and whether Lp(a) contributes to CAD [27,28] in this population remain controversial. Some investigators found elevated Lp(a) levels in subjects with IDDM compared with normoglycemic co...

show abstract

“…Secondly it could also be thrombogenic in large vessels other than the coronary arteries, for example the renal veins. Finally it could also have a role in the progression of renal disease (17).…”

Section: Discussionmentioning

confidence: 99%

Serum Lp(a) in diabetics with and without evidence of clinical nephropathy—A preliminary study

Kumari

Jayaram

Vincent

et al. 2002

Indian J Clin Biochem

View full text Add to dashboard Cite

Type 2 diabetes is associated with a marked increase in the risk of coronary artery disease. Dyslipidaemia is believed to be a major cause of this increased risk. Recently, elevated levels of lipoprotein (a), Lp(a), have been reported to be associated with an increased risk. However there is very little data regarding Lp(a) concentrations and type 2 diabetes from India. The objective of the study was to assess serum Lp(a) levels in type 2 diabetics with and with out evidence of clinical nephropathy. We estimated serum Lp(a) levels in 30 control subjects, 30 diabetics without evidence of clinical nephropathy and 30 diabetics with evidence of clinical nephropathy. Statistical analysis showed that Lp(a) levels were increased in diabetic patients with nephropathy (mean 46.3+_17.6 mg/dl). The Lp(a) levels however did not differ significantly between control (mean 20.2 _+15.9 mg/dl) and diabetics without nephropathy (mean 22.6 +-13.1 mg/dl). Thus diabetes per se seems to have little or no influence on serum Lp(a) levels, however elevated levels were seen in patients with nephropathy.

show abstract

Lipoprotein (a) in patients with proteinuria

Cited by 53 publications

References 0 publications

Lipoprotein(a) Serum Levels and Apolipoprotein(a) Phenotypes in Children with Chronic Renal Disease

Lipoprotein(a) Serum Levels and Apolipoprotein(a) Phenotypes in Children with Chronic Renal Disease

Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial

Serum Lp(a) in diabetics with and without evidence of clinical nephropathy—A preliminary study

Contact Info

Product

Resources

About